Antibody and protein discovery at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

80 organizations at PEGS Europe 2026 present work in discovery and display: 60 suppliers and service providers, 10 drug developers and 10 academic, government and non-profit bodies. Between them they bring 106 presentations to the program. Most represented: AstraZeneca (12 on the program), iBET (7 on the program), Merck KGaA (4 on the program). As of Oct 8, 2026.

All 541 organizations at PEGS Europe 2026 →

Showing 1–7 of 80 organizations

Organization	PEGS Europe 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company with oncology, immunology, respiratory and rare disease medicines, including antibodies and ADCs.	Talk Tue Nov 17 9:30am–10:00am Building the Protein Lab of the Future at AstraZeneca: Automation First Science and AI Ready Data at Scale Leveraging Data Science for Enhanced Protein Expression Chair Tue Nov 17 11:44am–11:45am Chairperson's Remarks Display of Biologics Chair Tue Nov 17 2:00pm–2:05pm Chairperson's Remarks Display of Biologics Talk Tue Nov 17 5:20pm–5:50pm Machine Learning for Lead Optimisation Workflow (MeLLOw): Integrating in silico and Wet Lab Data for Biologics Engineering Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with Specifica, Merck KGaA, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Talk Tue Nov 17 5:50pm–6:20pm Engineering Affinity Attenuated and Effector CD8 Biased T Cell Engagers T Cell Engagers Chair Wed Nov 18 8:25am–8:30am Chairperson’s Remarks Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:15am–11:45am Stability Prediction for Multispecific Antibodies Machine Learning for Protein Engineering Part 1 Talk Wed Nov 18 11:45am–12:15pm Application of Expression Strategies for Integral Membrane Protein Production Designing High-Performance Expression Platforms Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 8:30am–8:50am Evolutionary Algorithms for Peptide Design and Optimisation Novel Peptide Drug Discovery Talk Thu Nov 19 9:00am–9:30am Next-Generation Protein Characterisation: An Integrated Mass Spectrometry Strategy from Structured Proteins to Intrinsically Disordered Proteins Highly Parallel Protein Discovery Workflows Talk Thu Nov 19 11:15am–11:45am Targeting Peptides for Enhanced Tissue Delivery Novel Peptide Drug Discovery Talk Thu Nov 19 11:45am–12:05pm AI for Biologics: Transition from Discovery to Design Machine Learning for Protein Engineering Part 2 Talk Thu Nov 19 5:15pm–5:45pm Optimal Design of Masks for Protease-Activated Biologics: What Works, What Doesn’t, and Why Next-Generation Immunotherapies
iBET Oeiras, Portugal	◆Corporate Support Sponsor
ibet.pt AcademicCorporate Support Sponsor Portuguese non-profit research institute doing protein production, antibody discovery and bioprocess work, including contract research for industry.	Booth Exhibiting at Booth 123 Tue, Nov 1710:30am–7:50pmWed, Nov 1810:30am–5:30pmThu, Nov 1910:00am–2:00pm Chair Tue Nov 17 8:25am–8:30am Chairperson's Welcome Remarks Leveraging Data Science for Enhanced Protein Expression Talk Tue Nov 17 5:20pm–5:50pm The Development of iSeRa-AI, a Tool for Automatic Selection of mAbs from Antibody Display Coupled to Deep Sequencing Display of Biologics Talk Tue Nov 17 5:50pm–6:20pm 3D Tumour Microenvironments Enable Mechanistic Profiling of ADCs and Immunomodulatory Antibodies Safety and Efficacy of Bispecific and Multispecific Antibodies Talk Wed Nov 18 11:15am–11:45am Integrating Genome-Wide CRISPR Screening and Host Cell Engineering in HeLaS3 Producer Lines for rAAV Production Designing High-Performance Expression Platforms Talk Wed Nov 18 7:00pm–7:30pm Decoding Macrophage-Fibroblast Cross-Talk to Enable Next-Generation Anti-Fibrotic Therapies Analytical Characterisation of Biotherapeutics Talk Thu Nov 19 8:30am–9:00am Advanced Bioanalytics for Comprehensive Characterisation of Biotherapeutics Manufacturing Highly Parallel Protein Discovery Workflows Panel Thu Nov 19 5:05pm–5:45pm Higher-Throughput Biopharmaceutical Workflow Challenges Highly Parallel Protein Discovery Workflows · with University of Surrey, University College London, Septerna +1 more
Merck KGaA Darmstadt, Germany
merckgroup.com Large pharma German science and technology group whose healthcare business develops antibodies, ADCs and other biologics; it also runs a life science tools business.	Talk Tue Nov 17 3:05pm–3:35pm Integrating AI/ML and Next-Generation Sequencing for Accelerated Discovery of Single Domain Antibodies Display of Biologics Talk Tue Nov 17 4:50pm–5:20pm Digitalizing ADC Discovery: Building an Integrated Data and Workflow Platform Optimisation & Developability Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with AstraZeneca, Specifica, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Chair Thu Nov 19 8:25am–8:30am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Chair Thu Nov 19 10:44am–10:45am Chairperson's Remarks Engineering the Next Generation of Bispecific Antibodies Talk Thu Nov 19 10:45am–11:15am Decoding Photodegradation of ADC Payloads: Integrating in silico Modelling with Experimental Evidence to Understand and Predict Stability Protein Stability & Formulation Talk Thu Nov 19 4:45pm–5:15pm Multifunctional Antibody-Derived Receptor Agonists for Targeted Immunomodulation Next-Generation Immunotherapies
Specifica Santa Fe, NM
specifica.bio Discovery platforms IQVIA antibody discovery business offering Generation 3 and VHH display libraries, discovery and optimisation services, and platform transfer.	Panel Tue Nov 17 5:50pm–6:20pm BEST PRACTICES FOR IN SILICO DESIGN OF ANTIBODIES: What We Know Now Display of Biologics · with AstraZeneca, Merck KGaA, Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Talk Wed Nov 18 12:15pm–12:45pm Evolution of Specifica’s Gen3 Technology: Functional Bispecifics Directly from Constant Light Chain Libraries Engineering Antibodies & Beyond Panel Thu Nov 19 3:36pm–4:14pm Appropriate Use of Agentic AI in the Lab Machine Learning for Protein Engineering Part 2 · with Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI) Chair Thu Nov 19 4:14pm–4:15pm Chairperson's Remarks Machine Learning for Protein Engineering Part 2
University of Surrey Guildford, UK
	Panel Tue Nov 17 6:20pm–6:50pm Beyond the Bench: Harnessing Data to Advance Protein Science Leveraging Data Science for Enhanced Protein Expression · with University College London, Data Powered Therapeutics, Adaptyv Bio +1 more Talk Thu Nov 19 10:45am–11:15am Immune Checkpoint Inhibitor Therapies: Building on the Revolution to Improve Patient Outcomes Next-Generation Immunotherapies Talk Thu Nov 19 2:05pm–2:35pm Considerations for Integrating Workflows for Protein Production and Characterisation to Enable Quality Data Generation for Building ML Models Highly Parallel Protein Discovery Workflows Panel Thu Nov 19 3:35pm–4:15pm Clinical Outcomes in Immunotherapy—Where Are We Now? Next-Generation Immunotherapies · with Accession Therapeutics, BioInvent, Immatics +2 more Panel Thu Nov 19 5:05pm–5:45pm Higher-Throughput Biopharmaceutical Workflow Challenges Highly Parallel Protein Discovery Workflows · with University College London, Septerna, iBET +1 more
Affilogic Nantes, France
affilogic.com Biotech Develops Nanofitins, small non-antibody protein scaffolds, for targeted delivery and therapeutics.	Talk Wed Nov 18 11:15am–11:45am Bus2Brain: A Nanofitin-Based Platform for Targeted Brain Delivery of Oligonucleotide Therapeutics Engineering Next-Generation Conjugates Panel Wed Nov 18 5:00pm–5:30pm Young Scientist Meet Up Plenary · with ETH Zurich Talk Thu Nov 19 11:15am–11:45am Miniaturisation-Driven Acceleration of Expression and Screening Workflows Highly Parallel Protein Discovery Workflows
BOKU University Vienna, Austria
boku.ac.at Academic Vienna's University of Natural Resources and Life Sciences, with biotechnology research groups working on protein engineering and expression.	Talk Wed Nov 18 11:45am–12:15pm In vivo Control of CAR-Ts with Drug-Responsive Protein Switches Engineered by Directed Evolution Advances in Immunoengineering Chair Wed Nov 18 5:25pm–5:30pm Chairperson's Remarks Advances in Immunoengineering Talk Thu Nov 19 2:35pm–3:05pm From BacMam to Breakthrough: REMBAC for Tunable Expression and Stable Cell Line Engineering Highly Parallel Protein Discovery Workflows